CompletedPhase 3ACTRN12605000694617

SCOTROC 4

SCOTROC 4: A Prospective, Multicentre, Randomised Trial of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation in First Line Chemotherapy of Ovarian, Fallopian Tube and Primary Peritoneal Cancers, to improve progression-free survival.

Sponsor

SGCTG (and also investigator initiated)

Enrollment

1,300 participants

Start Date

Jan 24, 2006

Study Type

Interventional

Conditions

Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Summary

To assess in a formal protocol whether or not an intrapatient dose-escalation strategy for carboplatin can produce an improved outcome over flat dosing.

Eligibility

Sex: FemalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

The SCOTROC 4 study tests chemotherapy treatments for women with ovarian cancer, fallopian tube cancer, or peritoneal cancer who are not suitable for or unwilling to have standard platinum-taxane combination therapy. Women aged 18 and older with confirmed ovarian-type cancer may be eligible. Participants would receive an alternative chemotherapy regimen and have regular monitoring.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Chemotherapy: Carboplatin given over 6 cycles, 3 weekly.

Locations(1)

New Zealand

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000694617